Effect of anti-tumor necrosis factor α treatment on radiographic progression in patient with ankylosing spondylitis: A systematic review and meta-analysis

References

• Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–90.
   PubMed Web of Science ®Google Scholar
• Uckun A, Sezer I. Ankylosing spondylitis and balance. Eurasian J Med. 2017;49(3):207–10.
   PubMed Web of Science ®Google Scholar
• Maas F, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, et al. Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study. PLoS One. 2015;10(4):e0122693.
   PubMed Web of Science ®Google Scholar
• Protopopov M, Sieper J, Haibel H. Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Res Ther. 2017;19(1):240.
   PubMedGoogle Scholar
• Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis. 2007;66(7):910–5.
   PubMed Web of Science ®Google Scholar
• Heijde D. v d, Landewé R, Baraliakos X, Houben H, Tubergen A. v, Williamson P, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 2008;58(10):3063–70.
   PubMedGoogle Scholar
• Wanders AJB, Landewé RBM, Spoorenberg A, Dougados M, van der Linden S, Mielants H, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum. 2004;50(8):2622–32.
   PubMedGoogle Scholar
• Creemers MC, Franssen MJ, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1):127–9.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RGW. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol. 2010;37(8):1728–34.
   PubMed Web of Science ®Google Scholar
• Luchetti MM, Benfaremo D, Ciccia F, Bolognini L, Ciferri M, Farinelli A, et al. Adalimumab efficacy in enteropathic spondyloarthritis: a 12-mo observational multidisciplinary study. Wjg. 2017;23(39):7139–49.
   PubMed Web of Science ®Google Scholar
• Hu Z, Xu M, Li Q, Lin Z, Liao Z, Cao S, et al. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. Int J Rheum Dis. 2012;15(4):358–65.
   PubMed Web of Science ®Google Scholar
• Navarro-Sarabia F, Fernandez-Sueiro JL, Torre-Alonso JC, Gratacos J, Queiro R, Gonzalez C, et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxf). 2011;50(10):1828–37.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008;58(5):1324–31.
   PubMed Web of Science ®Google Scholar
• Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010;37(6):1203–10.
   PubMed Web of Science ®Google Scholar
• van Weely SFE, Kneepkens EL, Nurmohamed MT, Dekker J, van der Horst-Bruinsma IE. Continuous improvement of physical functioning in ankylosing spondylitis patients by tumor necrosis factor inhibitors: three-year followup and predictors. Arthritis Care Res (Hoboken). 2016;68(10):1522–9.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Rudwaleit M. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis. 2005;64(10):1462–6.
   PubMed Web of Science ®Google Scholar
• van der Linden S, Valkenburg HA. Evaluation of diagnostic criteria for ankylosing spondylitis A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
   PubMed Web of Science ®Google Scholar
• Kang KY, Ju JH, Park S-H, Kim H-Y. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis. Rheumatology (Oxf). 2013;52(4):718–26.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Chiowchanwisawakit P, Lambert RGW, Ostergaard M, Maksymowych WP. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol. 2011;38(7):1349–54.
   PubMed Web of Science ®Google Scholar
• Kim T-J, Shin J-H, Kim S, Sung I-H, Lee S, Song Y, et al. Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data. Joint Bone Spine. 2016;83(5):569–72.
   PubMed Web of Science ®Google Scholar
• Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(8):2091–102.
   PubMed Web of Science ®Google Scholar
• Dougados M, Braun J, Szanto S, Combe B, Elbaz M, Geher P, et al. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis. 2011;70(5):799–804.
   PubMed Web of Science ®Google Scholar
• Dougados M, Braun J, Szanto S, Combe B, Geher P, Leblanc V, et al. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology (Oxf). 2012;51(9):1687–96.
   PubMed Web of Science ®Google Scholar
• Huang F, Gu J, Zhu P, Bao C, Xu J, Xu H, et al. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis. 2014;73(3):587–94.
   PubMed Web of Science ®Google Scholar
• Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, et al. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatology (Oxf). 2014;53(9):1654–63.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis. 2014;73(4):710–5.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxf). 2007;46(9):1450–3.
   PubMed Web of Science ®Google Scholar
• Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis VI Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23(4):540–51.
   PubMed Web of Science ®Google Scholar
• Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNF α blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241–8.
   PubMed Web of Science ®Google Scholar
• Machado M. A d Á, Barbosa MM, Almeida AM, de Araújo VE, Kakehasi AM, Andrade EIG, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33(9):2199–213.
   PubMed Web of Science ®Google Scholar
• Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology(Oxf). 2010;49(7):1317–25.
   PubMed Web of Science ®Google Scholar
• Ulusoy H, Kaya A, Kamanli A. Radiological scoring methods in ankylosing spondylitis: a comparison of the reliability of available methods. Acta Reumatol Port. 2010;35(2):170–5.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91.
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC, Heijde DVD, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58(11):3402–12.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BAC, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46.
   PubMed Web of Science ®Google Scholar
• Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MMS, Tanjong Ghogomu E, et al. TNF–alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;(4):CD005468. doi: 10.1002/14651858.CD005468.pub2
   PubMed Web of Science ®Google Scholar
• Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol. 2011;7(12):700–7.
   PubMed Web of Science ®Google Scholar